New insights into the pathogenesis of adenosine deaminase-severe combined immunodeficiency and progress in gene therapy

Current Opinion in Allergy and Clinical Immunology

Volumn 9, Issue 6, 2009, Pages 496-502

  Sauer, Aisha V ^a,b   Aiuti, Alessandro ^a,c  

^a SAN RAFFAELE SCIENTIFIC INSTITUTE   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Adenosine deaminase; Adenosine deaminase severe combined immunodeficiency; Gene therapy; Severe combined immunodeficiency

Indexed keywords

ADENOSINE DEAMINASE DEFICIENCY; AUTOIMMUNITY; CYTOTOXICITY; GENE EXPRESSION; GENE THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOPATHOGENESIS; IN VIVO STUDY; LONG TERM CARE; MOLECULAR CLONING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PURINE METABOLISM; REGULATORY T LYMPHOCYTE; REVIEW;

ADENOSINE DEAMINASE; ANIMALS; CLINICAL TRIALS AS TOPIC; GENETIC VECTORS; HUMANS; LYMPHOID PROGENITOR CELLS; SEVERE COMBINED IMMUNODEFICIENCY; STEM CELL TRANSPLANTATION; TARGETED GENE REPAIR; TRANSDUCTION, GENETIC; VIRUSES;

EID: 70350771061     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e3283327da5     Document Type: Review

References (41)

1. Hirschhorn R, Candotti F. Immunodeficiency due to defects of purine metabolism. In: Ochs H, Smith C, Puck J, editors. Primary immunodeficiency diseases. Oxford: Oxford University Press; 2006. pp. 169-196.
2. Aiuti A, Slavin S, Aker M, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002; 296:2410-2413.
3. Booth C, Hershfield M, Notarangelo L, et al. Management options for adenosine deaminase deficiency; proceedings of the EBMT satellite workshop (Hamburg, March 2006). Clin Immunol 2007; 123:139-147.
4. Hershfield MS. Combined immune deficiencies due to purine enzyme defects. Immunologic Disorders in Infants and Children. 5th ed. Philadelphia: Saunders; 2004:480-504.
5. Kohn DB, Candotti F. Gene therapy fulfilling its promise. N Engl J Med 2009; 360:518-521.
6. Cassani B, Mirolo M, Cattaneo F, et al. Altered intracellular and extracellular signaling leads to impaired T-cell functions in ADA-SCID patients. Blood 2008; 111:4209-4219.
7. Notarangelo LD, Stoppoloni G, Toraldo R, et al. Insulin-dependent diabetes mellitus and severe atopic dermatitis in a child with adenosine deaminase deficiency. Eur J Pediatr 1992; 151:811-814.
8. Ozsahin H, Arredondo-Vega FX, Santisteban I, et al. Adenosine deaminase deficiency in adults. Blood 1997; 89:2849-2855.
9. Mazzolari E, de Martiis D, Forino C, et al. Single-center analysis of long-term outcome after hematopoietic cell transplantation in children with congenital severe T cell immunodeficiency. Immunol Res 2009; 44:4-17.
10. Neven B, Leroy S, Decaluwe H, et al. Long-term outcome after haematopoietic stem cell transplantation of a single-centre cohort of 90 patients with severe combined immunodeficiency: long-term outcome of HSCT in SCID. Blood 2009; 113:4114-4124.
11. Aiuti A, Cattaneo F, Galimberti F, et al. Long-term safety and efficacy of gene therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency. New Engl J Med 2009; 360:447-458.
12. Sitkovsky M, Lukashev D, Deaglio S, et al. Adenosine A2A receptor antagonists: blockade of adenosinergic effects and T regulatory cells. Br J Pharmacol 2008; 153 (Suppl 1):S457-S464.
13. Aiuti A, Ficara F, Cattaneo F, et al. Gene therapy for adenosine deaminase deficiency. Curr Opin Allergy Clin Immunol 2003; 3:461-466.
14. Bollinger ME, Arredondo-Vega FX, Santisteban I, et al. Brief report: hepatic dysfunction as a complication of adenosine deaminase deficiency. N Engl J Med 1996; 334:1367-1371.
15. Sauer AV, Mrak E, Jofra Hernandez R, et al. ADA-deficient SCID is associated with a specific microenvironment and bone phenotype characterized by RANKL/OPG imbalance and osteoblast insufficiency. Blood 2009 (in press).
16. Rogers MH, Lwin R, Fairbanks L, et al. Cognitive and behavioral abnormalities in adenosine deaminase deficient severe combined immunodeficiency. J Pediatr 2001; 139:44-50.
17. Honig M, Albert MH, Schulz A, et al. Patients with adenosine deaminase deficiency surviving after hematopoietic stem cell transplantation are at high risk of CNS complications. Blood 2007; 109:3595-3602.
18. Titman P, Pink E, Skucek E, et al. Cognitive and behavioral abnormalities in children after hematopoietic stem cell transplantation for severe congenital immunodeficiencies. Blood 2008; 112:3907-3913.
19. Zhou Y, Mohsenin A, Morschl E, et al. Enhanced airway inflammation and remodeling in adenosine deaminase-deficient mice lacking the A2B adenosine receptor. J Immunol 2009; 182:8037-8046.
20. Blaese RM, Culver KW, Miller AD, et al. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 1995; 270:475-480.
21. Bordignon C, Notarangelo LD, Nobili N, et al. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients. Science 1995; 270:470-475.
22. Onodera M, Ariga T, Kawamura N, et al. Successful peripheral T-lymphocytedirected gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency. Blood 1998; 91:30-36.
23. Kohn DB, Hershfield MS, Carbonaro D, et al. T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34p cells in ADA-deficient SCID neonates. Nat Med 1998; 4:775-780.
24. Ficara F, Superchi DB, Hernandez RJ, et al. IL-3 or IL-7 increases ex vivo gene transfer efficiency in ADA-SCID BM CD34p cells while maintaining in vivo lymphoid potential. Mol Ther 2004; 10:1096-1108.
25. Kohn DB. Gene therapy for childhood immunological diseases. Bone marrow transplant 2008; 41:199-205.
26. Aiuti A, Brigida I, Ferrua F, et al. Hematopoietic stem cell gene therapy for adenosine deaminase deficient-SCID. Immunol Res 2009; 44:150-159.
27. Baum C, Kustikova O, Modlich U, et al. Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors. Hum Gene Ther 2006; 17:253-263.
28. Ott MG, Schmidt M, Schwarzwaelder K, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006; 12:401-409.
29. Hacein-Bey-Abina S, Garrigue A, Wang GP, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008; 118:3132-3142.
30. Howe SJ, Mansour MR, Schwarzwaelder K, et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 2008; 118:3143-3150.
31. Aiuti A, Cassani B, Andolfi G, et al. Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. J Clin Invest 2007; 117:2233-2240.
32. Dave UP, Akagi K, Tripathi R, et al. Murine leukemias with retroviral insertions at Lmo2 are predictive of the leukemias induced in SCID-X1 patients following retroviral gene therapy. PLoS Genet 2009; 5:e1000491.
33. Shou Y, Ma Z, Lu T, Sorrentino BP. Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy. Proc Natl Acad Sci U S A 2006; 103:11730-11735.
34. Cassani B, Montini E, Maruggi G, et al. Integration of retroviral vectors induces minor changes in the transcriptional activity of T cells from ADA-SCID patients treated with gene therapy. Blood 2009 (in press).
35. Recchia A, Bonini C, Magnani Z, et al. Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells. Proc Natl Acad Sci U S A 2006; 103:1457-1462.
36. Montini E, Cesana D, Schmidt M, et al. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest 2009; 119:964-975.
37. Mortellaro A, Hernandez RJ, Guerrini MM, et al. Ex vivo gene therapy with lentiviral vectors rescues adenosine deaminase (ADA)-deficient mice and corrects their immune and metabolic defects. Blood 2006; 108:2979-2988.
38. Carbonaro DA, Jin X, Cotoi D, et al. Neonatal bone marrow transplantation of ADA-deficient SCID mice results in immunological reconstitution despite low levels of engraftment and an absence of selective donor T lymphoid expansion. Blood 2008; 111:5745-5754.
39. Carbonaro DA, Jin X, Petersen D, et al. In vivo transduction by intravenous injection of a lentiviral vector expressing human ADA into neonatal ADA gene knockout mice: a novel form of enzyme replacement therapy for ADA defi-ciency. Mol Ther 2006; 13:1110-1120.
40. Williams DA. Gene therapy continues to mature and to face challenges. Mol Ther 2009; 17:1305-1306.
41. Gaspar HB, Aiuti A, Porta F, et al. How I treat ADA deficiency. Blood 2009 (in press).